R&D Removing barriers in treatment-resistant depression pharmaphorum speaks with Hans Eriksson, psychiatrist and CMO of FundaMental Pharma, about why treatment resistance remains such a challenge.
Patients Breaking Bipolar I disorder stigma in the Hispanic community For many Hispanic patients and families, that is where the gap between need and treatment can begin.
Patients Decline in overdose deaths ≠ The end of the opioid crisis Since 2001, International Overdose Day has been observed as a moment to remember those lost to overdose and renew society’s commitment to
News Entropy, UCSF Pre-CTA for Ph2 psilocin vs Lexapro in MDD Entropy signs Pre-CTA with UCSF to develop a US-based Phase 2 trial comparing IV psilocin treatment directly against escitalopram (Lexapro) in MDD.
Patients In schizophrenia care, even the support system needs support After a schizophrenia diagnosis, families must learn how to navigate treatment, respond to symptoms, and communicate effectively.
Digital Callyope's AI-powered solution for mental health practitione... The state of the public’s mental health in the UK and Europe is a serious unmet need.
News RNAi biotech City hauls in $200m in upsized IPO City Therapeutics has finalised its IPO, raising $200 million for a pipeline of RNA interference therapies headed by a novel anticoagulant.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.